Celularity's Late 10-Q Reveals Going Concern Warning, $368K Cash, and Material Weaknesses
CELU has more than doubled off its 52-week low of $0.56.
Summary
Celularity's late Q1 2026 10-Q reveals going concern doubt, $368K cash, a $64.3M working capital deficit, and six material weaknesses in financial controls. The reported profit was entirely from a one-time tax loss sale.
Key Events · Earnings and Guidance · CELU
-
Going Concern Warning
Management states substantial doubt about Celularity's ability to continue as a going concern within 12 months. Cash is $368K with a $64.3M working capital deficit.
-
Revenue Collapse
Total revenue fell 66.3% year-over-year to $3.8M, driven by a 90.4% drop in product sales due to Medicare reimbursement uncertainty.
-
Misleading Net Income
Reported net income of $874K was entirely from a one-time $12.2M sale of NJ net operating loss carryforwards. Excluding that, operations used cash.
-
Material Weaknesses
Six material weaknesses in internal control over financial reporting disclosed, including insufficient qualified resources and privileged ERP access.
Analysis · CELU · Life Sciences
The long-delayed Q1 2026 report paints a picture of severe distress. Cash has dwindled to $368K against a $64.3M working capital deficit, and management explicitly states substantial doubt about its ability to continue as a going concern. The reported net income of $874K is misleading — it was entirely driven by a one-time $12.2M sale of New Jersey tax loss carryforwards; excluding that, operations burned cash. Revenue collapsed 66% year-over-year to $3.8M. The filing also discloses six material weaknesses in internal controls, explaining the chronic late filings that triggered multiple Nasdaq delisting notices. This is the first time investors see the full Q1 picture, and it confirms the worst fears behind the recent financing scramble.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 43.9% of the 285 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.